Barinthus Biotherapeutics (NASDAQ:BRNS) Releases Quarterly Earnings Results, Beats Expectations By $0.23 EPS

Barinthus Biotherapeutics (NASDAQ:BRNS) released its quarterly earnings data on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23, RTT News reports. The firm had revenue of $14.97 million for the quarter. During the same period last year, the firm posted ($0.37) earnings per share.

Barinthus Biotherapeutics Trading Down 8.3 %

NASDAQ BRNS traded down $0.12 during trading hours on Friday, hitting $1.35. 43,853 shares of the company’s stock traded hands, compared to its average volume of 23,685. The business’s fifty day moving average price is $1.29 and its two-hundred day moving average price is $1.57. The firm has a market capitalization of $53.22 million, a P/E ratio of -0.91 and a beta of -0.59. Barinthus Biotherapeutics has a 52 week low of $1.11 and a 52 week high of $4.16.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Alliance Global Partners dropped their price objective on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Barinthus Biotherapeutics in a research report on Friday.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.